In the BioHarmony Drug Report Database

"Preview" Icon

Telotristat etiprate

Xermelo (telotristat etiprate) is a small molecule pharmaceutical. Telotristat etiprate was first approved as Xermelo on 2017-02-28. It is used to treat diarrhea and malignant carcinoid syndrome in the USA. Xermelo’s patents are valid until 2031-02-27 (FDA).

 

Trade Name

 

Xermelo
 

Common Name

 

telotristat etiprate
 

ChEMBL ID

 

CHEMBL3348963
 

Indication

 

diarrhea, malignant carcinoid syndrome
 

Drug Class

 

Enzyme inhibitors: tryptophan hydroxylase inhibitors

Image (chem structure or protein)

Telotristat etiprate structure rendering